Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ExposureDefinition: Therapeutic-dose anticoagulation with heparin - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="179786"/>
  <meta>
    <versionId value="3"/>
    <lastUpdated value="2023-12-04T20:30:40.963Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-definition"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 179786</b></p><a name="179786"> </a><a name="hc179786"> </a><a name="179786-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 3; Last updated: 2023-12-04 20:30:40+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-exposure-definition.html">ExposureDefinition</a></p></div><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786.)</p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>url</b>: <a href="https://fevir.net/resources/Group/179786">https://fevir.net/resources/Group/179786</a></p><p><b>identifier</b>: FEvIR Object Identifier/179786</p><p><b>name</b>: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin</p><p><b>title</b>: ExposureDefinition: Therapeutic-dose anticoagulation with heparin</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Description: therapeutic-dose anticoagulation with heparin
Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.</p>
</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: Any of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>ATTACC investigational arm</p>
</div><h3>Timings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen&gt;24 hours, provided oxygen was required), whichever comes first.</td></tr></table></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>ACTIV-4a investigational arm</p>
</div><h3>Timings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge, whichever comes first.</td></tr></table></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by CodeableConcept</span></p><p><b>value</b>: <span title="Codes:">Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>REMAP-CAP investigational arm</p>
</div><h3>Timings</h3><table class="grid"><tr><td style="display: none">-</td><td><b>ContextCode</b></td><td><b>Offset[x]</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Start of trial</span></td><td>0-14</td><td>Up to 14 days or until hospital discharge, whichever comes first.</td></tr></table></blockquote></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786."/>
    </valueRelatedArtifact>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <url value="https://fevir.net/resources/Group/179786"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179786"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name
        value="ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin"/>
  <title
         value="ExposureDefinition: Therapeutic-dose anticoagulation with heparin"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="Description: therapeutic-dose anticoagulation with heparin
Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="any-of"/>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="ATTACC investigational arm"/>
    <timing>
      <contextCode>
        <text value="Start of trial"/>
      </contextCode>
      <offsetRange>
        <low>
          <value value="0"/>
        </low>
        <high>
          <value value="14"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </high>
      </offsetRange>
      <text
            value="Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen&gt;24 hours, provided oxygen was required), whichever comes first."/>
    </timing>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal."/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="ACTIV-4a investigational arm"/>
    <timing>
      <contextCode>
        <text value="Start of trial"/>
      </contextCode>
      <offsetRange>
        <low>
          <value value="0"/>
        </low>
        <high>
          <value value="14"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </high>
      </offsetRange>
      <text
            value="Up to 14 days or until hospital discharge, whichever comes first."/>
    </timing>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels."/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="REMAP-CAP investigational arm"/>
    <timing>
      <contextCode>
        <text value="Start of trial"/>
      </contextCode>
      <offsetRange>
        <low>
          <value value="0"/>
        </low>
        <high>
          <value value="14"/>
          <unit value="days"/>
          <system value="http://unitsofmeasure.org"/>
          <code value="d"/>
        </high>
      </offsetRange>
      <text
            value="Up to 14 days or until hospital discharge, whichever comes first."/>
    </timing>
  </characteristic>
</Group>